| Company Name: |
Energy Chemical |
| Tel: |
400-0056266 |
| Email: |
sales8178@energy-chemical.com |
MANNAN manufacturers
- MANNAN
-
-
2026-06-30
- CAS:9036-88-8
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 10000KGS
- Mannan
-
- $29.00
-
2026-05-11
- CAS:9036-88-8
- Purity:
- Supply Ability: 10g
|
| | MANNAN Chemical Properties |
| refractive index | 78.5 ° (C=1.4, H2O) | | storage temp. | 2-8°C | | form | powder | | color | Off-white to light yellow | | biological source | Saccharomyces cerevisiae | | Optical Rotation | [α]25/D 73 to 82 °, c =1% (w/v) in water | | Water Solubility | water: ~50g/L | | Merck | 5744 | | Cosmetics Ingredients Functions | FILM FORMING | | Cosmetic Ingredient Review (CIR) | MANNAN (9036-88-8) | | CAS DataBase Reference | 9036-88-8 |
| Hazard Codes | Xi | | Risk Statements | 36/37/38 | | Safety Statements | 22-26-36-24/25 | | WGK Germany | 3 | | RTECS | OP1949500 | | Storage Class | 11 - Combustible Solids |
| | MANNAN Usage And Synthesis |
| Uses | Mannan from Saccharomyces cerevisiae has been used in a study to assess nonopsonic uptake of Mycobacterium avium complex by human monocytes and alveolar macrophages. It has also been used in a study to investigate new lectins from bulbs of Croccus sativum. | | General Description | Mannan from Saccharomyces cerevisiae is a simple polysaccharide. | | Biological Activity | Mannan exhibits several biological properties, including antiproliferative, antioxidant, and immunomodulatory. It is used as a hardener ingredient and as an emulsion stabilizer. Mannan is also involved in the inhibition of pathogen adherence, regulation of bacterial growth, and enhancement of the immune response. | | in vivo | Mannan (50-500 ppm; p.o., dietary; daily; 4 weeks) reduces Aflatoxin B1 (HY-N6615)-induced toxicity in mice, as evidenced by increased body weight, decreased rate of normochromatic erythrocytes with micronuclei, and decreased rate of sister chromatid exchanges[2].
Mannan (50-100 mg/kg; i.p.; 2-5 times) reduces serum levels of low-density lipoprotein (LDL), cholesterol, and triglycerides in mice with acute dyslipidemia induced by poloxamer 407 (HY-D1005)[4].
| Animal Model: | Male CBA/Lac mice (2.5-3-month-old, weighing 22-25 g), acute lipemia induced by poloxamer 407 model[4] | | Dosage: | 50 mg/kg, 100 mg/kg | | Administration: | Intraperitoneal injection, 5 times at 50 mg/kg every other day or 2 times at 100 mg/kg with 1-day interval | | Result: | Reduced the levels of triglyceride, atherogenic LDL, and total cholesterol in the serum at 50 mg/kg and 100 mg/kg.
Decreased the triglyceride concentration in the liver.
Increased the lability of lysosomal membranes in the liver and elevated the serum activity of chitotriosidase, a marker of macrophage activation.
|
|
| | MANNAN Preparation Products And Raw materials |
|